PDGFRB and neoplasm: Additionally, these compounds presented potent inhibition against the tumor growth-related tyrosine multiple kinase targets FGFR3, IGF1R, PDGFRb, and TRKB at a concentration of <10.4 μM, except for 151, which showed weak activity, with IC50 > 25 μM [46].